Program Signaling and Experimental Therapeutics

项目总结（见说明）： 癌症信号传导与实验治疗 癌症信号传导和实验治疗学（CSET）计划的研究重点是细胞信号传导途径以及它们如何影响癌症进展和治疗。该计划成员的总体目标是阐明与肿瘤生物学相关的基本信号传导机制，并将这些知识应用于新治疗方法的发现和开发。该计划的研究中有两个主要的重叠主题：第一个主题是癌症信号传导，由三个相互关联的研究领域组成; GTP酶和激酶，激素信号传导和细胞粘附信号传导。第二个主题是实验治疗学，包括三个相互关联的研究领域：药物输送和RNA干扰，小分子和临床试验。在过去的资助期间，癌症信号传导和实验治疗计划的主要成就包括确定乳腺癌雌激素受体信号传导的新治疗靶点，将新型类异戊二烯抗癌化合物推进临床前验证研究，以及开发基于RNA适体的RNA干扰系统性递送。过去和现在，该计划的成员之间以及与其他癌症中心计划的成员之间都有许多富有成效的合作。例如在 该项目的共同领导人Hohl博士和Wiemer博士合作开发了具有抗癌活性的新型类异戊二烯化合物，并将其推向临床试验，项目领导人亨利博士分别与癌症遗传学和计算生物学以及癌症流行病学项目的领导人Quelle博士和Lynch博士分享了NCI和NIH的单独资助，并在最近与Dr. 巴拉斯癌症免疫学和免疫治疗计划的负责人。该计划由来自7个基础科学和8个临床部门和3个学院的45名成员组成。同行评审，该计划的研究资金总额为980万美元，其中350万美元来自NCI。项目成员发表了339篇与癌症有关的文章 上一个财政年度的预算。在这些出版物中，8%是计划内的，27%是计划间的，2%是计划内和计划间的，总共37%是合作出版物。

PROJECT SUMMARY (See instructions): Cancer Signaling and Experimental Therapeutics Research in the Cancer Signaling and Experimental Therapeutics (CSET) Program focuses cell signaling pathways and how they impact cancer progression and therapy. The overall goal of the members of this program is to elucidate basic signaling mechanisms relevant to tumor biology and apply this knowledge to the discovery and development of new therapeutic approaches. There are two major overiapping themes within the Program's research: The first theme is Cancer Signaling and is comprised of three interrelated research areas; GTPases and kinases, hormonal signaling and cell adhesion signaling. The second theme is Experimental Therapeutics and is comprised of three interrelated research areas; drug delivery and RNA interference, small molecules and clinical trials. Major accomplishments of the Cancer Signaling and Experimental Therapeutics Program over the past funding period include identification of a new therapeutic target in estrogen receptor signaling in breast cancer, advancement of novel isoprenoid anti-cancer compounds into pre-clinical validation studies, and development of RNA-aptamer-based systemic delivery of RNA-interference in prostate cancer. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. For example, within the program Co-leader Dr. Hohl and Dr. Wiemer have collaborated to develop novel isoprenoid compounds with anti-cancer activity and advance these toward clinical trials and Program Leader Dr. Henry shares separate NCI and NIH grant funding with Drs. Quelle and Lynch, Leaders of the Cancer Genetics and Computational Biology and Cancer Epidemiology programs, respectively and has published recently with Dr. Ballas Leader of the Cancer Immunology and Immunotherapy program. The program consists of 45 members from 7 basic science and 8 clinical departments and 3 Colleges. Peer-reviewed, research funding for this program totals $9.8 million with $3.5 million coming from the NCI. Program members published 339 cancer related papers over the prior funding period. Of these publications, 8% were intraprogrammatic, 27% were interprogrammatic and 2% were both intra and interprogrammatic, for a total of 37% collaborative publications.